evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 6 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 2 · 28.6%Low 0 · 0%Moderate 3 · 42.9%High 1 · 14.3%

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Serious adverse events ‐ total · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo

Serious adverse events by total adverse events · patients with upper gastrointestinal bleeding and liver diseases.

Recombinant human factor VII activated showed no clear difference in serious adverse events by total adverse events compared with placebo (high certainty).

1 finding from 1 review

Diacerein vs placebo

Total number of serious adverse events not measured · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).

1 finding from 1 review